Taking advantage of drug resistance, a new approach in the war on cancer

Frontiers of Medicine
Liqin Wang, Rene Bernards

Abstract

Identification of the driver mutations in cancer has resulted in the development of a new category of molecularly targeted anti-cancer drugs. However, as was the case with conventional chemotherapies, the effectiveness of these drugs is limited by the emergence of drug-resistant variants. While most cancer therapies are given in combinations that are designed to avoid drug resistance, we discuss here therapeutic approaches that take advantage of the changes in cancer cells that arise upon development of drug resistance. This approach is based on notion that drug resistance comes at a fitness cost to the cancer cell that can be exploited for therapeutic benefit.We discuss the development of sequential drug therapies in which the first therapy is not given with curative intent, but to induce a major new sensitivity that can be targeted with a second drug that selectively targets the acquired vulnerability. This concept of collateral sensitivity has hitherto not been used on a large scale in the clinic and holds great promise for future cancer therapy.

References

Jul 6, 2002·Science·I Bernard Weinstein
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Jun 6, 2012·The New England Journal of Medicine·Keith T FlahertyUNKNOWN METRIC Study Group
Sep 27, 2013·Science Translational Medicine·Lejla Imamovic, Morten O A Sommer
Jun 24, 2014·Nature Reviews. Molecular Cell Biology·Daniel Muñoz-Espín, Manuel Serrano
Sep 23, 2014·Trends in Biochemical Sciences·Chong Sun, René Bernards
Oct 16, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott KopetzLeonard Saltz
Mar 1, 2016·Cell·Boyang ZhaoMichael T Hemann
Jun 16, 2016·Cell Metabolism·Christopher D Wiley, Judith Campisi
Mar 16, 2017·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Nicolai TreiberDirk Debus
Apr 5, 2017·Nature Reviews. Clinical Oncology·Jason J LukeGeorgina V Long
Jul 6, 2017·Nature·Vasanthi S ViswanathanStuart L Schreiber
Nov 2, 2017·Nature·Matthew J HangauerMichael T McManus

❮ Previous
Next ❯

Citations

May 16, 2019·Cellular and Molecular Life Sciences : CMLS·Winnie Fong, Kenneth K W To
Aug 7, 2020·Dalton Transactions : an International Journal of Inorganic Chemistry·Yuyu ZhongJianqiang Liu
Mar 10, 2019·Biochemical Society Transactions·Ian J Majewski
Oct 1, 2019·British Journal of Cancer·Alessandro LeonettiMarcello Tiseo
Jan 27, 2019·Oncotarget·Maja T Tomicic, Markus Christmann
Jul 1, 2020·Nature·Verena Wagner, Jesús Gil
Dec 5, 2019·Nature Metabolism·Ana GuerreroJesús Gil
May 7, 2021·Molecular Oncology·Matheus Henrique Dias, René Bernards
Jan 1, 2021·ACS Applied Materials & Interfaces·Tao GuoGuoming Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

© 2022 Meta ULC. All rights reserved